Education
About Us
Working with TipRanks
Follow Us
Argenx Se (ARGX)
NASDAQ:ARGX
Earnings Data
Report Date
Feb 26, 2026TBA (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
6.15Last Year’s EPS
11.79Same Quarter Last Year
Strong Buy
Based on 21 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call reflected strong financial performance and successful product launches, particularly the PFS, alongside significant pipeline progress. However, there were setbacks in certain pipeline developments and increased operating expenses. Despite this, the positives of revenue growth and successful commercial strategies outweigh the negatives.Company Guidance
Record-Breaking Revenue and Growth
Argenx reported total product net sales of $1.13 billion in Q3 2025, surpassing $1 billion in VYVGART sales in a single quarter for the first time. This represents a 19% growth from the previous quarter and a 96% growth year-over-year.
Successful PFS Launch
The prefilled syringe (PFS) is driving increased demand, with over 50% of new patients starting on PFS. This has expanded the prescriber base, with over 260 new prescribers writing their first VYVGART prescriptions.
Strong Performance Across Geographies
Product net sales breakdown: $964 million in the U.S., $60 million in Japan, $94 million in other global markets, and $9 million for product supply to Zai Lab in China.
Pipeline Progress
Argenx now has 3 first-in-class molecules in Phase III development and expects to begin Phase III studies for Graves' disease early next year.
Positive Data in MG
VYVGART showed up to 60% of patients reaching minimum symptom expression with 83% maintaining it for at least 8 weeks. Additionally, over 55% of patients reduced steroid use to below 5 mg/day after 18 months.
ARGX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ARGX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Oct 30, 2025 | $821.97 | $820.36 | -0.20% |
Jul 31, 2025 | $598.89 | $670.33 | +11.93% |
May 08, 2025 | $622.93 | $569.12 | -8.64% |
Feb 27, 2025 | $623.02 | $624.70 | +0.27% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Argenx Se (ARGX) report earnings?
Argenx Se (ARGX) is schdueled to report earning on Feb 26, 2026, TBA (Confirmed).
What is Argenx Se (ARGX) earnings time?
Argenx Se (ARGX) earnings time is at Feb 26, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ARGX EPS forecast?
ARGX EPS forecast for the fiscal quarter 2025 (Q4) is 6.15.